Publications by authors named "Marta Guix"

Claim this Profile
C
ColoStem, a core oncofetal signature that identifies poor prognosis colorectal tumors.
Laura Solé, Eric Canton, María Maqueda, Teresa Lobo-Jarne, Antonio Barbáchano, Marta Guix

Br J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Case of Peritoneal Carcinomatosis After Hyperprogression in Human Papillomavirus-Positive (HPV+) Oropharyngeal Squamous Cell Carcinoma.
Rafael Bach, Alex Corbera, Anna Sumarroca, Javier Gimeno, Marta Guix

Cureus· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients.
Laura Solé, Teresa Lobo-Jarne, Júlia-Jié Cabré-Romans, Antón González, Lierni Fernández, Marta Guix

Biochim Biophys Acta Mol Cell Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.
Joana Vidal, Maria Concepción Fernández-Rodríguez, David Casadevall, Pilar García-Alfonso, David Páez, Marta Guix

Clin Cancer Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis.
Laura Solé, Teresa Lobo-Jarne, Daniel Álvarez-Villanueva, Josune Alonso-Marañón, Yolanda Guillén, Marta Guix

Nat Commun· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era.
Joaquim Bellmunt, Emilio Esteban, Xabier García Del Muro, Juan Manuel Sepúlveda, Pablo Maroto, Marta Guix

Eur Urol Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients.
Miren Taberna, Montserrat Torres, María Alejo, Marisa Mena, Sara Tous, Marta Guix

Front Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma.
María José Méndez-Vidal, Áurea Molina, Urbano Anido, Isabel Chirivella, Olatz Etxaniz, Marta Guix

BMC Pharmacol Toxicol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HPV-relatedness definitions for classifying HPV-related oropharyngeal cancer patient do impact on TNM classification and patients' survival.
Miren Taberna, Marisa Mena, Sara Tous, Miquel Angel Pavón, Marc Oliva, Marta Guix

PLoS One· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and Predictive Factors for Renal Cell Carcinoma.
Cristina Suárez, Marc Campayo, Romà Bastús, Sergi Castillo, Olatz Etxanitz, Marta Guix

Target Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double positivity for HPV-DNA/p16 is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients.
Marisa Mena, Miren Taberna, Sara Tous, Sandra Marquez, Omar Clavero, Marta Guix

Oral Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.
Swati Biswas, Marta Guix, Cammie Rinehart, Teresa C Dugger, Anna Chytil

J Clin Invest· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.
Rafael Morales-Barrera, Joaquim Bellmunt, Cristina Suárez, Claudia Valverde, Marta Guix

Eur J Cancer· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.
Todd W Miller, Marianela Pérez-Torres, Archana Narasanna, Marta Guix, Olle Stål

Cancer Res· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations.
Joaquim Bellmunt, Marta Guix

BJU Int· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of biological agents targeted at early-stage disease.
Marta Guix, Ingrid A Mayer, Ingrid M Meszoely, Carlos L Arteaga

Breast Cancer Res· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Albert Font, Ramon Salazar, Joan Maurel, Miquel Taron, Jose Luis Ramirez, Marta Guix

Cancer Chemother Pharmacol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.
Shizhen Emily Wang, Bin Xiang, Marta Guix, Maria Graciela Olivares, Joel Parker

Mol Cell Biol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
Marta Guix, Anthony C Faber, Shizhen Emily Wang, Maria Graciela Olivares, Youngchul Song

J Clin Invest· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Marta Guix, Nara de Matos Granja, Ingrid Meszoely, Theresa B Adkins, Bobbye M Wieman

J Clin Oncol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
Christoph A Ritter, Marianela Perez-Torres, Cammie Rinehart, Marta Guix, Teresa Dugger

Clin Cancer Res· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer.
Li Yang, Joseph M Amann, Takefumi Kikuchi, Rut Porta, Marta Guix

Cancer Res· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.
Swati Biswas, Marta Guix, Cammie Rinehart, Teresa C Dugger, Anna Chytil

J Clin Invest· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
Marianela Perez-Torres, Marta Guix, Adriana Gonzalez, Carlos L Arteaga

J Biol Chem· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.
Josep Tabernero, Fredy Rojo, Irene Marimón, Maurizio Voi, Joan Albanell, Marta Guix

J Clin Oncol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis